RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN
多西紫杉醇、阿霉素和环磷酰胺的随机 II 期研究
基本信息
- 批准号:7716656
- 负责人:
- 金额:$ 5.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-20 至 2008-11-30
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdjuvant ChemotherapyBiological PreservationBreastBreast CarcinomaCity of Hope Comprehensive Cancer CenterClinical ResearchCollaborationsComputer Retrieval of Information on Scientific Projects DatabaseCyclophosphamideDNA FingerprintingERBB2 geneFundingFutureGrantIn complete remissionInstitutionNormal tissue morphologyOutcomePatientsPhaseProtein AnalysisRNARandomizedRateResearchResearch PersonnelResourcesSourceStagingTranslational ResearchUnited States National Institutes of Healthchemotherapydocetaxelmalignant breast neoplasmmultidisciplinaryprognostictumor
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Neo-adjuvant chemotherapy may allow breast preservation and down staging in patients with primary breast cancer. Higher pathological complete response rates following neo-adjuvant chemotherapy may predict for prolonged survival. This study will attempt to define a less toxic and potentially more effective neo-adjuvant regiment in patients with both HER-2 positive and HER-2 negative Stage II-III breast carcinoma. This neo-adjuvant setting also allows for exploratory analysis of protein profiles, DNA and RNA profiles of the tumor and normal tissue prior to and subsequent to chemotherapy in order to identify predictive and prognostics indicators of outcomes and potential targets for future therapy. This project will represent multidisciplinary and translational research collaborations amongst the clinical and research entities of the City of Hope Comprehensive Cancer Center.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE SOMLO其他文献
GEORGE SOMLO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE SOMLO', 18)}}的其他基金
RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN
多西紫杉醇、阿霉素和环磷酰胺的随机 II 期研究
- 批准号:
7982070 - 财政年份:2008
- 资助金额:
$ 5.77万 - 项目类别:
RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN
多西紫杉醇、阿霉素和环磷酰胺的随机 II 期研究
- 批准号:
7603885 - 财政年份:2006
- 资助金额:
$ 5.77万 - 项目类别:
RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADRIAMYCIN AND CYTOXAN
多西他赛、阿霉素和环磷酰胺的随机 II 期研究
- 批准号:
7368184 - 财政年份:2005
- 资助金额:
$ 5.77万 - 项目类别:
DOSE-INTENSE CHEMOTHERAPY AND STEM CELL RESCUE IN THE TREATMENT OF INFLAMMATORY
炎症治疗中的大剂量化疗和干细胞拯救
- 批准号:
7368147 - 财政年份:2005
- 资助金额:
$ 5.77万 - 项目类别:
PHASE II RANDOMIZED TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB AND THALIDOMIDE
贝伐珠单抗与贝伐珠单抗和沙利度胺的 II 期随机试验
- 批准号:
7199954 - 财政年份:2004
- 资助金额:
$ 5.77万 - 项目类别:
Phase II Randomized Trial of Bevacizumab vs. Bevacizumab
贝伐珠单抗与贝伐珠单抗的 II 期随机试验
- 批准号:
7040118 - 财政年份:2003
- 资助金额:
$ 5.77万 - 项目类别:
Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory
大剂量化疗和干细胞拯救治疗炎症
- 批准号:
7040100 - 财政年份:2003
- 资助金额:
$ 5.77万 - 项目类别:
DOSE INTENSE CHEMOTHERAPY & STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER
剂量强化化疗
- 批准号:
6421113 - 财政年份:2000
- 资助金额:
$ 5.77万 - 项目类别:
DOSE INTENSE CHEMOTHERAPY & STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER
剂量强化化疗
- 批准号:
6303635 - 财政年份:1999
- 资助金额:
$ 5.77万 - 项目类别:
DOSE INTENSE CHEMOTHERAPY & STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER
剂量强化化疗
- 批准号:
6263716 - 财政年份:1998
- 资助金额:
$ 5.77万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 5.77万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 5.77万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 5.77万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 5.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 5.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 5.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 5.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 5.77万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 5.77万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 5.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)